Regulated cell death pathways: New twists in modulation of BCL2 family function

Nidhish Sasi, Misun Hwang, Jerry Jaboin, Ildiko Csiki, Bo Lu

Research output: Contribution to journalShort survey

76 Citations (Scopus)

Abstract

A number of cell death pathways have been recognized. Though apoptosis and autophagy have been well characterized, programmed necrosis has recently received attention and may provide clinical alternatives to suppress resistant tumors. Necrosis is primarily characterized by large-scale permeabilization, swelling, and rupture of cell membranes and the release of pro-inflammatory cytokines. Traditionally, necrosis in cancer cells has been indicative of poor prognoses, as chronic inflammation was found to encourage tumor growth. Yet, many antitumor effects associated with necrosis have been discovered in certain settings, such as the formation of an effective antitumor immune response. In this way, finding ways to attenuate the pro-tumor effects of necrosis while engaging the antitumor pathways via drugs, radiation, and sensitization may prove valuable as a clinical focus for the future. We hypothesize that the use of Bcl-2 inhibitors may enhance necrotic death characterized by inflammation and antitumor immunity. In this article, we briefly review apoptosis and autophagy and reason how necrosis may be a suitable alternative therapeutic endpoint. We then highlight novel inhibitors of Bcl-2 that may provide clinical application of our hypothesis in the future.

Original languageEnglish (US)
Pages (from-to)1421-1429
Number of pages9
JournalMolecular Cancer Therapeutics
Volume8
Issue number6
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Cell Death
Necrosis
Autophagy
Neoplasms
Apoptosis
Inflammation
Rupture
Immunity
Cell Membrane
Radiation
Cytokines
Growth
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Regulated cell death pathways : New twists in modulation of BCL2 family function. / Sasi, Nidhish; Hwang, Misun; Jaboin, Jerry; Csiki, Ildiko; Lu, Bo.

In: Molecular Cancer Therapeutics, Vol. 8, No. 6, 06.2009, p. 1421-1429.

Research output: Contribution to journalShort survey

Sasi, Nidhish ; Hwang, Misun ; Jaboin, Jerry ; Csiki, Ildiko ; Lu, Bo. / Regulated cell death pathways : New twists in modulation of BCL2 family function. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 6. pp. 1421-1429.
@article{2e1326dcd6b4433c95d87800e132266f,
title = "Regulated cell death pathways: New twists in modulation of BCL2 family function",
abstract = "A number of cell death pathways have been recognized. Though apoptosis and autophagy have been well characterized, programmed necrosis has recently received attention and may provide clinical alternatives to suppress resistant tumors. Necrosis is primarily characterized by large-scale permeabilization, swelling, and rupture of cell membranes and the release of pro-inflammatory cytokines. Traditionally, necrosis in cancer cells has been indicative of poor prognoses, as chronic inflammation was found to encourage tumor growth. Yet, many antitumor effects associated with necrosis have been discovered in certain settings, such as the formation of an effective antitumor immune response. In this way, finding ways to attenuate the pro-tumor effects of necrosis while engaging the antitumor pathways via drugs, radiation, and sensitization may prove valuable as a clinical focus for the future. We hypothesize that the use of Bcl-2 inhibitors may enhance necrotic death characterized by inflammation and antitumor immunity. In this article, we briefly review apoptosis and autophagy and reason how necrosis may be a suitable alternative therapeutic endpoint. We then highlight novel inhibitors of Bcl-2 that may provide clinical application of our hypothesis in the future.",
author = "Nidhish Sasi and Misun Hwang and Jerry Jaboin and Ildiko Csiki and Bo Lu",
year = "2009",
month = "6",
doi = "10.1158/1535-7163.MCT-08-0895",
language = "English (US)",
volume = "8",
pages = "1421--1429",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Regulated cell death pathways

T2 - New twists in modulation of BCL2 family function

AU - Sasi, Nidhish

AU - Hwang, Misun

AU - Jaboin, Jerry

AU - Csiki, Ildiko

AU - Lu, Bo

PY - 2009/6

Y1 - 2009/6

N2 - A number of cell death pathways have been recognized. Though apoptosis and autophagy have been well characterized, programmed necrosis has recently received attention and may provide clinical alternatives to suppress resistant tumors. Necrosis is primarily characterized by large-scale permeabilization, swelling, and rupture of cell membranes and the release of pro-inflammatory cytokines. Traditionally, necrosis in cancer cells has been indicative of poor prognoses, as chronic inflammation was found to encourage tumor growth. Yet, many antitumor effects associated with necrosis have been discovered in certain settings, such as the formation of an effective antitumor immune response. In this way, finding ways to attenuate the pro-tumor effects of necrosis while engaging the antitumor pathways via drugs, radiation, and sensitization may prove valuable as a clinical focus for the future. We hypothesize that the use of Bcl-2 inhibitors may enhance necrotic death characterized by inflammation and antitumor immunity. In this article, we briefly review apoptosis and autophagy and reason how necrosis may be a suitable alternative therapeutic endpoint. We then highlight novel inhibitors of Bcl-2 that may provide clinical application of our hypothesis in the future.

AB - A number of cell death pathways have been recognized. Though apoptosis and autophagy have been well characterized, programmed necrosis has recently received attention and may provide clinical alternatives to suppress resistant tumors. Necrosis is primarily characterized by large-scale permeabilization, swelling, and rupture of cell membranes and the release of pro-inflammatory cytokines. Traditionally, necrosis in cancer cells has been indicative of poor prognoses, as chronic inflammation was found to encourage tumor growth. Yet, many antitumor effects associated with necrosis have been discovered in certain settings, such as the formation of an effective antitumor immune response. In this way, finding ways to attenuate the pro-tumor effects of necrosis while engaging the antitumor pathways via drugs, radiation, and sensitization may prove valuable as a clinical focus for the future. We hypothesize that the use of Bcl-2 inhibitors may enhance necrotic death characterized by inflammation and antitumor immunity. In this article, we briefly review apoptosis and autophagy and reason how necrosis may be a suitable alternative therapeutic endpoint. We then highlight novel inhibitors of Bcl-2 that may provide clinical application of our hypothesis in the future.

UR - http://www.scopus.com/inward/record.url?scp=67649362253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649362253&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-0895

DO - 10.1158/1535-7163.MCT-08-0895

M3 - Short survey

C2 - 19509269

AN - SCOPUS:67649362253

VL - 8

SP - 1421

EP - 1429

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -